A method for emptying a device for producing granules or extrudates. The device includes a container having an inlet for the material to be treated, an inlet for a liquid, a stirring device, an outlet for said intermediate product, and an emptying pipe having an inlet for the intermediate product and an outlet for the granules or extrudate as well as a conveying device conveying the intermediate product from the inlet of the emptying pipe in the direction of the outlet of the emptying pipe. The method includes the steps of: producing the intermediate product from the material to be treated and the liquid in the container; moving the emptying pipe from the closed position with respect to the container into an open position with respect to the container; and conveying the intermediate product from the container and via the conveying devices.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

A reactor for coating particles includes a stationary vacuum chamber to hold a bed of particles to be coated, a vacuum port in an upper portion of the chamber, a chemical delivery system configured to inject a reactant or precursor gas into a lower portion of the chamber, a paddle assembly, and a motor to rotate a drive shaft of the paddle assembly. The lower portion of the chamber forms a half-cylinder. The paddle assembly includes a rotatable drive shaft extending through the chamber along the axial axis of the half cylinder, and a plurality of paddles extending radially from the drive shaft such that rotation of the drive shaft by the motor orbits the plurality of paddles about the drive shaft.

Shown are a particulate processed product of tea and a method for preparing the same. The particulate processed product of tea has a sphericity S.sub.10 value of a particle corresponding to 10% cumulative subdistribution in cumulative distribution measured for the sphericity of tea particles of 0.68 or greater. The processed product of tea is convenient to drink because it is readily wetted and dispersed in water. In addition, it can be easily packaged and used due to a low angle of repose and thus excellent flowability.

A wet granulator includes a material cylinder. A cylinder cover is rotatably arranged at an opening of the material cylinder, and a locking member is arranged on the cylinder cover. The locking member includes a locking housing, and the locking housing is provided with a first through groove. A locking pin slides in the first through groove, and the locking pin includes a middle rod and a contacting rod. A first end of the contacting rod is connected to a first end of the middle rod to form a contacting platform, and a second end of the contacting rod extends out of the first through groove. The first end of the middle rod is arranged in the first through groove, and a second end of the middle rod extends out of the first through groove. The second end of the middle rod is provided with a pin head.

A wet granulator includes a material cylinder. A cylinder cover is rotatably arranged at an opening of the material cylinder, and a locking member is arranged on the cylinder cover. The locking member includes a locking housing, and the locking housing is provided with a first through groove. A locking pin slides in the first through groove, and the locking pin includes a middle rod and a contacting rod. A first end of the contacting rod is connected to a first end of the middle rod to form a contacting platform, and a second end of the contacting rod extends out of the first through groove. The first end of the middle rod is arranged in the first through groove, and a second end of the middle rod extends out of the first through groove. The second end of the middle rod is provided with a pin head.

A manufacturing method of a particle aggregate aggregated with wet particles in which active material particles and conductive particles are evenly dispersed and a manufacturing method of an electrode body including the particle aggregate are provided. The manufacturing method of a particle aggregate includes a first step of obtaining a first mixture by mixing conductive particles with a binder dispersion in which binder is dispersed in a dispersion medium, a second step of obtaining a clay-like mixture by kneading the first mixture with active material particles, and a third step of obtaining the particle aggregate aggregated with wet particles formed of the clay-like mixture.

A manufacturing method of a particle aggregate aggregated with wet particles in which active material particles and conductive particles are evenly dispersed and a manufacturing method of an electrode body including the particle aggregate are provided. The manufacturing method of a particle aggregate includes a first step of obtaining a first mixture by mixing conductive particles with a binder dispersion in which binder is dispersed in a dispersion medium, a second step of obtaining a clay-like mixture by kneading the first mixture with active material particles, and a third step of obtaining the particle aggregate aggregated with wet particles formed of the clay-like mixture.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.